Longer Chemo Regimen Offers Better DFS For Premenopausal Breast Cancer
Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable
FDA Approves Gleevec For First Line Rx Of CML
Fragmin Cuts Risk Of VE By 50 Percent In Study
Sirolimus-Containing Therapy Reduces GVHD, Study Finds
Avastin Regimen Bested Chemo Alone In Early Disease
Paraplatin Lengthened TTP In HER2+ Advanced Breast Ca
Study Confirms Cancer Risk Increase Due To Combined HRT
Pill Associated With Cancer In BRCA1 Mutation Carriers
National Cancer Institute Lists Approved Clinical Trials
Trending Stories
- Abdallah Abou Zahr, an oncologist whose cancer story resonated widely, dies of liposarcoma at 42
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
- Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill
- On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors
